Mini-Device implanted in tumors could reveal which drug works best

NCT ID NCT06782399

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Oliver Jonas Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a tiny implantable device that delivers very small amounts of several approved cancer drugs directly into skin cancer tumors. The goal is to see if the device can safely and effectively identify which drug triggers the most cancer cell death in that specific tumor. The study involves 25 people with squamous cell carcinoma and focuses on whether the device can be placed and removed without damaging the tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Microdevice (implantable nanodose drug delivery device releasing multiple approved drugs)
What this could lead to
If successful, this could lead to a way to quickly test which drugs are most effective for a person's specific skin cancer, making treatment more personalized and efficient.
What could go wrong
This is a very early, small pilot study (25 people) focused on whether the device can be safely placed and removed. It does not test if the drugs actually shrink tumors, so many more studies would be needed before this approach could be used in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dana Farber Cancer Insitute

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.